Pharmacological and Non-pharmacological Treatments of Sleep Disorders in Parkinson's Disease

Reyisha Taximaimaiti1, Xingguang Luo2 and Xiao-Ping Wang1,*

1Department of Neurology, Shanghai TongRen Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200336, China; 2Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA

Abstract: Sleep disorders are one of the most common non-motor symptoms in Parkinson's disease (PD). It can cause a notable decrease in quality of life and functioning in PD patients, as well as place a huge burden on both patients and caregivers. The most cited sleep disorders in PD included insomnia, restless legs syndrome (RLS), rapid eye movement (REM), sleep behavior disorders (RBD), excessive daytime sleepiness (EDS) and sleep disordered breathing (SDB), which can appear alone or several at the same time. In this review, we listed the recommended pharmacological treatments for common sleep disorders in PD, and discussed the recommended dosages, benefits and side effects of relative drugs. We also discussed non-pharmacological treatments to improve sleep quality, including sleep hygiene education, exercise, deep brain stimulation, cognitive behavior therapy and complementary therapies. We tried to find proper interventions for different types of sleep disorders in PD, while minimizing relative side effects.

Keywords: Parkinson's disease, insomnia, restless legs syndrome, RBD, excessive daytime sleepiness, sleep disordered breathing, pharmacological treatments, non-pharmacological treatments.

1. INTRODUCTION

Sleep disorders, as one of the most common non-motor symptoms in Parkinson's disease (PD), can occur at any stage in PD and place a huge burden on both patients and caregivers [1]. It is reported that 60%-98% PD patients experience sleep disturbances, and up to 60% even suffer from sleep disturbances long before any obvious motor symptom appears [2]. Despite the high prevalence, only less than half of sleep problems are reported to doctors and receive enough attention [3]. Sleep disorders are related to decreased cognitive function, increased risk of falls and worsen quality of life (QOL) [4, 5]. It will not only increase motor dysfunction but also increase the non-motor symptom burden [6]. In addition to health risks, sleep disorders can also bring significant socio-economic consequences. Patients and society must bear higher healthcare costs and other indirect costs, such as loss of labor market income [7].

Sleep disorders have increasingly been considered as an inherent component of the degenerative process itself, associated with neuronal degeneration and both α-synuclein and tau deposition in key structures involved in sleep cycle and maintenance, such as the locus coeruleus, raphe nuclei, paraventricular and posterior hypothalamic nuclei, amygdala, and thalamus [8]. In humans, the level of arousal and alternations of sleep-wake cycle is controlled by the hypothalamus and a number of brainstem nuclei. [8]. Specifically, the major wakefulness-promoting areas, including the hypothalamus, the pedunculopontine nucleus (PPN), the locus coeruleus and the raphe nuclei; and the major sleep-promoting nucleus is the ventrolateral preoptic nucleus of the anterior hypothalamus [9, 10]. Dopaminergic system plays an important role in the sleep-wake cycle. Dopamine (DA) in the basal ganglia (BG) promotes sleep via D2 receptors, while the extra-BG dopaminergic system promotes wakefulness via D1 and D2 receptors [11]. At the same time, in animal models, researchers found that the release of DA increased in the dark period and decreased in the light period, which indicating DA activity might have circadian rhythm [12]. The pathology of PD is characterized by degeneration of DA neurons in the pars compacta of substantia nigra (SN), which results in a marked DA depletion in the striatum [13]. DA neurons in SN innervate not only the striatum but also other BG nuclei, including globus pallidus and subthalamic nuclei [14]. When DA neurons in SN are degenerated to a certain degree, which leads to a significant depletion of DA in BG and extra-BG dopaminergic system, the sleep-wake cycle of PD patients will be disrupted and various types of sleep disorders appear [13].

Most cited sleep disorders in PD include insomnia, restless legs syndrome (RLS), rapid eye movement (REM), sleep behavior disorders (RBD), excessive daytime sleepiness (EDS) and sleep disordered breathing (SDB) [15, 16].
They may occur one or more at a time and sometimes share the same treatment. Common methods for detecting sleep disorders in PD include detailed medical history, questionnaires about sleep quality, and polysomnography. Recommend questionnaires include but are not limited to Parkinson’s Disease Sleep Scale (PDSS), Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), and Stanford sleepiness scale (SSS) [17].

Management of sleep disorders in PD should start with sleep hygiene education and effective non-pharmacological treatments. Pharmacological management usually begins with optimization of antiparkinsonian therapy, especially alternations of dopaminergic drugs. Then according to different types of sleep disorders, specialized and personalized drugs are given. Although many drugs have proved to have certain therapeutic effects on sleep disorders, the overall treatment effects in PD population are still far from satisfactory with effect discrepancy and various side effects. Thus, it is of vital importance to choose the right treatments and drug dosage for different types of sleep disorders.

This review discussed common sleep disorders in PD patients and listed pharmacological and non-pharmacological interventions to alleviate them and improve sleep quality. We listed the recommended pharmacological treatments for common sleep disorders in PD, and discussed the recommended dosages, benefits and side effects of related drugs. We tried to find a proper way to select personalized pharmacological and non-pharmacological interventions for different types of sleep disorders in PD, while improving patients’ tolerance and minimize side effects.

2. SLEEP DISORDERS AND PHARMACOLOGICAL TREATMENTS

2.1. Insomnia

Insomnia is the most common sleep disorder in PD. It can happen in 30% to 80% PD patients and sometimes exists long before obvious motor dysfunction appears [18]. Patients with insomnia can seldom initiate, maintain, and consolidate sleep or often fail to keep a good sleep quality overnight despite satisfying environment [15]. The most common insomnia subtype in PD is sleep maintenance obstacle, which is also called sleep fragmentation [19]. Studies have demonstrated that chronic sleep fragmentation can cause cognitive impairment in PD patients, especially impairments in executive functions, including deficits in attention, phonemic verbal fluency, and working memory [19, 20].

Insomnia in PD is a result of the mixture of factors. It can be partly explained by overnight PD motor symptoms, non-motor symptoms like nocturia and nocturnal pain, depression, effect of antiparkinsonian medications, autonomic dysfunction, and comorbid sleep-wake regulatory disorders [21, 18]. Nighttime PD motor and non-motor symptoms can be improved by antiparkinsonian medications, but these medications can reversely cause or exacerbate insomnia. DA agonists (e.g. ropinirole, rotigotine, pramipexole, cabergoline and pergolide), selegiline, rasagiline and entacapone are all reported to have a risk to induce or exacerbate insomnia [22-29]. Other drugs associated with insomnia include selective serotonin reuptake inhibitors (e.g. fluvoxamine, sertraline, and fluoxetine), the acetylcholinesterase inhibitors (e.g. galantamine, donepezil, and rivastigmine), and the serotonin–norepinephrine reuptake inhibitor (venlafaxine) [30].

But the paradox is that some of these drugs can also be used to treat insomnia or other types of sleep disorders, which makes it difficult to adjust patients’ medication plans. Clinically, PD patients with higher Unified Parkinson’s Disease Rating Scale (UPDRS) scores, longer disease duration, female, depression, anxiety and motor fluctuations are more likely to experience insomnia [31]. And some studies reveal that patients with insomnia will experience less time in REM, but whether that means less chance to develop RBD still need further research [32].

The first step to manage insomnia in PD is to evaluate whether antiparkinsonian medicines need adjustment (Table 1). Although DA preparations like carbidopa–levodopa controlled release can improve nocturnal akinesia, there is not enough evidence on improving subjective and objective sleep quality [33]. DA agonist can significantly improve PD patients’ subjective and objective sleep quality. Studies have demonstrated that DA agonists can improve both motor and non-motor PD symptoms and permit a reduction in adjunctive levodopa dose, making it a choice to manage insomnia [34]. But it can also cause daytime somnolence and sudden sleep attack [30]. Different types of DA agonists also show different effects. Specifically, sustained-release preparations improved subjective sleep quality more than immediate-release preparations, without a significant increase in side effects. Rotigotine showed similar sleep-improving effects as pramipexole immediate release, but it is preferred more to individuals with motor fluctuations and insomnia at the same time [30, 35]. Also, DA agonists are demonstrated to have a dose-dependent effect; that is, higher doses induce wakefulness during sleep while lower doses reduce wakefulness and improve sleep quality [36]. This phenomenon is mainly related to the biphasic effects of D2 receptors, such that low doses reduce waking and increase slow wake sleep (SWS) and REM, whereas large doses induce opposite effects [36, 37]. There are also some reports that show continuous levodopa-carbidopa intestinal gel (LCIG) infusion that improves sleep quality in advanced PD patients [38]. Sustained LCIG treatment is recommended for advanced PD patients when conventional levodopa based oral or transdermal therapy is ineffective, and it can lead to significant improvements in motor fluctuations, non-motor symptoms, mood disorders, cognition impairment and gastrointestinal disorders. However, most of the relevant experiments are only performed in patients with advanced PD and the operation requirements are high, so it is still too early to make large-scale clinical applications.

Doxepin and quetiapine are atypical sedative antipsychotics frequently used to treat hallucinations and psychotic symptoms in PD [39]. It is believed that sedating antipsychotics cannot only treat mood disorders but also other comorbidities such as nighttime pain, which contributes to sleep quality improvement [40]. Doxepin and quetiapine are well tolerated in most PD patients, especially in those with dementia and impaired cognitive function, but they may also cause or aggravate other types of sleep disorders [41, 42].
Although side effects will remit after drug withdrawal, antipsychotics in PD patients should be used cautiously [39]. Nonbenzodiazepine hypnotics like eszopiclone are widely-used sleeping pills in insomnia. They have lower risks to suppress breathing and do not need too much specialized monitoring [43, 40]. 3-5mg melatonin and 2mg melatonin sustained release can also significantly improve the subjective quality of sleep, although objective sleep quality is not improved in polysonomography [44]. Agomelatine is an effective melatonergic antidepressant that has dual treatments for both sleep disorders and depression. It may have considerable therapeutic potential in PD patients for sleep problems and mood disorders that often occur at the same time [45]. Zonisamide has been used as a safe and effective add-on treatment when general PD therapy is not satisficatory to control motor/non-motor symptoms of PD. Its mechanism is related to inhibition of monoamine oxidase-B, modulation of the levodopa-dopamine metabolism and DA receptor expression [46]. Studies have also shown zonisamide can improve PD motor symptoms, sleep disturbances, impulse control disorders (ICD), depression, and cognitive impairment, making it a suitable choice for complex conditions of the elderly [46, 47].

Table 1. Pharmacological treatments of insomnia in PD patients.

| - | Recommended Dose | Benefits | Side Effects |
|---|---|---|---|
| **Dopaminergic agonists** | | | |
| Rotigotine | 2-16mg [47] | improve subjective sleep quality; improve overnight and early morning motor performance; reduce nocturia | local site reactions; dyskinesias; headache; dizziness; daytime somnolence; fatigue; nausea |
| Pramipexole immediate release | 0.375- 4.5 mg [48] | improve subjective sleep quality; improve overnight motor and non-motor symptoms | visual hallucinations; daytime somnolence; sudden sleep attack; fatigue; nausea; ICD; orthostatic hypotension; edema |
| Pramipexole sustained release | 0.375- 4.5 mg [48] | improve subjective sleep quality; improve overnight motor and non-motor symptoms | visual hallucinations; daytime somnolence; sudden sleep attack; fatigue; nausea; ICD; orthostatic hypotension; edema |
| Ropinirole | 0.75-15 mg [49] | improve subjective sleep quality; improve overnight motor and non-motor symptoms | dyskinesias; headache; dizziness; daytime somnolence; sudden sleep attack; nausea; leg edema |
| Ropinirole prolonged release | 2-24mg [34] | improve subjective sleep quality; improve overnight motor and non-motor symptoms | dyskinesia; hallucinations; daytime somnolence; dizziness; nausea; orthostatic hypotension; leg edema |
| Cabergoline | 4–6 mg [50] | improve subjective sleep quality; increase sleep efficiency and SWS | hallucinations; dizziness; daytime somnolence; nausea; cardiopulmonary fibrosis |
| **Sedative antipsychotics** | | | |
| Doxepin | 10 mg [51] | improve subjective sleep quality; reduce fatigue; improved scores of MoCA; | transient orthostatic; dizziness; fatigue; nausea |
| Quetiapine | 12.5-50 mg [39] | improve subjective sleep quality; reduce hallucinations | worsen PD motor symptoms; aggravate RLS; daytime somnolence; nausea |
| **Non-benzodiazepines** | | | |
| Eszopiclone | 2-3 mg [52] | improve subjective sleep quality; reduce number of awakenings after sleep onset | daytime somnolence; dizziness |
| **Melatonin and melatonin agonists** | | | |
| Melatonin | 3-5mg [44, 53] | improve subjective sleep quality | mild headaches; daytime somnolence; fatigue |
| Melatonin sustained release | 2mg [54, 55] | improve subjective sleep quality; reduce nocturia | mild headaches; daytime somnolence; fatigue |
| Agomelatine | 12.5–50 mg [45] | improve subjective sleep quality; improve depressive symptoms | headache; dizziness; fatigue; nausea |
| **Others** | | | |
| Zonisamide | 25-50 mg [46] | improve subjective sleep quality; improve PD motor symptoms; improve depressive symptoms | aggravate insomnia; increased blood creatine phosphokinase; decreased appetite; constipation |
| Levodopa-carbidopa intestinal gel | 1 dose [38] (containing 20 mg/ml levodopa and 5 mg/ml carbidopa) | improve subjective sleep quality; improve PD motor symptoms; improve mood, fatigue and cognition; improve gastrointestinal disorders | decreased weight; device related infections; device dislocations; device issues; polyneuropathy |
2.2. Restless Legs Syndrome (RLS)

RLS is described as an uncontrollable urge to move the legs in rest or inactivity, usually accompanied by unpleasant sensations and can be partially or totally relieved by movements [56]. The prevalence of RLS in general population is 4-10%, but the chance in PD patients (untreated and treated) is about two to three times more than that [57]. The prevalence of RLS in PD increases with the course of PD and the duration of PD drug treatment [58]. Although RLS has a high prevalence in PD, it is often overlooked. Some studies found that up to 40% of PD patients experience similar leg restless, but only 15% of them meet the diagnosis criteria of RLS [59]. And the real prevalence rate may be much higher than expected because PD and RLS share the same effective treatment with dopaminergic drugs, which may cover up RLS symptoms [60]. Compared to those without RLS, PD patients with RLS have significantly greater anxiety severity, depression severity and pain severity, which are associated with severe disability [61].

The pathologic mechanisms of RLS are not fully understood. DA dysfunction, iron deficiency, and genetic defects seem to play important roles in RLS pathology [62,63] but there are still questions about the pathology of RLS in PD. Specifically, no difference was seen in iron metabolism in PD patients with and without RLS, and dopaminergic neurons outside the blood-brain-barrier seemed to play an important role in RLS pathophysiology in PD patients, indicating idiopathic RLS and RLS in PD might have different pathogenesis [56, 64, 65]. What’s more, functional imaging study showed diminished regional homogeneity and functional connectivity within the precentral and postcentral gyri in PD patients with RLS, which implies that the functional abnormalities in sensorimotor network may disrupt the lateral pain pathway and contribute to RLS pathophysiology in PD [66]. RLS can also be a side effect of certain drugs like some antidepressants and neuroleptics [67]. Female, cognitive dysfunction and worse QOL are also reported to be associated with RLS in PD [60, 68-70].

Levodopa and DA agonists are reported to alleviate RLS in PD [56] (Table 2). Levodopa is the gold standard for PD treatment and is well tolerated for most PD patients. But it still has a risk of RLS symptom aggravation due to the augmentation syndrome, or RLS symptoms might rebound in the morning because of its short half-life [71]. Thus, the lowest-effective dose of levodopa using intermittently is

| Table 2. Pharmacological treatments of RLS in PD patients. |
|----------------------------------------------------------|
| **Recommended Dose** | **Benefits** | **Side Effects** |
| Levodopa | 200-300mg [80] | improve nighttime RLS symptoms; improve overnight motor and non-motor symptoms; reduce pain | aggravate RLS; symptoms rebound in the morning; dyskinesia |
| Dopaminergic agonists | | | |
| Pramipexole | 0.375-4.5 mg [74] | improve nighttime RLS symptoms; improve overnight motor and non-motor symptoms; reduce pain | visual hallucinations; daytime somnolence; sudden sleep attack; fatigue; nausea; ICD; orthostatic hypotension; edema |
| Ropinirole | 0.25-4.0mg [81] | improve nighttime RLS symptoms; improve overnight motor and non-motor symptoms | aggravate RLS; dyskinesias; headache; dizziness; daytime somnolence; nausea; leg edema |
| Rotigotine | 2-16mg [82] | improve nighttime RLS symptoms; improve overnight and early morning motor performance; reduce nocturia | local site reactions; dyskinesias; headache; dizziness; daytime somnolence; fatigue; nausea |
| α2δ ligands | | | |
| Gabapentin | 800 mg (100 mg for patients >65 years initial daily dose) (200 mg for patients with uraemia) [56, 83] | improve nighttime RLS symptoms; reduce pain | dizziness; daytime somnolence; peripheral edema |
| Pregabalin | 150-450 mg (50 mg for patients >65 years initial daily dose) [56, 83] | improve nighttime RLS symptoms; improve subjective nighttime sleep; reduce pain | dizziness; daytime somnolence; headache; fatigue |
| Gabapentin enacarbil | 600-1200 mg (300 mg for patients >65 years initial daily dose) [56, 83] | improve nighttime RLS symptoms; reduce pain | daytime somnolence; headache; fatigue |
| Others | 18-48 mg [84] | improve nighttime RLS symptoms; reduce pain and spasm | rebound morning stiffness; subcutaneous nodules |
recommended [62]. DA agonists are able to provide continuous effective doses in blood and are widely used in the treatment of RLS [72]. They should be administered 2 to 3 hours before bedtime to relieve RLS in PD [73] but DA agonists also have many side effects. For example, high doses of dopaminergic agonists can result in visual hallucinations that are dose-related [74]. Pramipexole has a higher risk of ICD compared to other DA agonists due to its affinity for the D3 receptor [74]. In PD patients with older ages, cognitive dysfunction and ICD, some studies suggest that DA agonists should be avoided and only levodopa is recommended; however, other recent studies published found DA agonists such as Rotigotine are safe in these patients, and they can bring greater motor and non-motor benefits at the same time [72, 75].

α2δ ligands like gabapentin, gabapentin enacarbil, and pregabalin are also demonstrated to be more or equivalently effective than DA agonists in idiopathic RLS. α2δ ligands can cause depression and weight gain, thus DA agonists are usually considered as the initial treatment for RLS [76]. While α2δ ligands do not have dopaminergic problems like augmentation, ICD, severe daytime somnolence, and hallucinations, and are more suitable for moderate to severe RLS patients [56], evidence also shows that, for severe RLS cases which α2δ ligands do not work, DA agonists are still effective [76] but studies about the efficacy of α2δ ligands on PD patients with RLS are still limited. Considering their quite common side effects, α2δ ligands should be used with caution in PD patients. Apomorphine is also effective for PD patients with RLS in some studies. It can relieve pain and spasm overnight and is good for improving the microstructure of sleep but it should only be regarded as a supplementary treatment when other treatments are ineffective in advanced PD [56]. Cabergoline 2-3 mg/d has a good evidence on improving nighttime RLS symptoms, but considering its severe side effects such as cardiopulmonary fibrosis, it is not currently used in clinic [72]. Iron therapy lacks enough evidence in treating RLS in PD, and might even cause opposite effect since the pathology PD seems to associate with oxidative damage caused by iron accumulation in the SN [77]. Opioids have been shown to be effective for refractory idiopathic RLS, but there is no research exploring their effects on PD patients with RLS. There are also reports about some other drugs treating RLS in PD, such as stradafylline, safinamide, and levodopa-carbidopa intestinal gel [56, 78, 79], but the sample sizes of related studies are too small to provide reliable conclusions.

2.3. REM Sleep Behavior Disorders (RBD)

RBD is a precursor of α-synucleinopathy in many neurodegenerative diseases [85]. It is characterized by muscle atonia loss during REM sleep and can cause dream enactment behaviors [86]. RBD is usually suspected through patient's self-report or spouse interview, and definitive diagnosis of RBD is made by polysomnography. Only 1% of adults had RBD, but this number for PD patients ranged from 30.0 to 62.5% [2]. RBD can appear before or after the development of motor symptoms of PD [87]. Prospective clinical studies have suggested that PD patients with RBD were disabled earlier than those without RBD. RBD can be regarded as a sign of motor function deterioration and poor prognosis [88-90]. Compared to those without RBD, PD patients with RBD are generally prone to experiencing more severe and complicated motor and non-motor symptoms [91]. Specifically, PD patients with RBD are more susceptible to more severe motor symptoms, more severe autonomic dysfunction, ICD, and require higher doses of levodopa therapy [19, 92]. They are also at a higher risk of non-motor symptoms, including constipation, hallucination, depression, and cognitive impairment [93-97]. All of these factors make RBD patients have a relatively lower QOL, and emphasize the importance of controlling RBD in PD patients [98].

RBD might result from dysfunction of the brainstem nucleus and brainstem locomotor centers [32]. A neuro-melanin-sensitive MRI study demonstrated decreased signal intensity within the locus coeruleus/subcoeruleus, which may involve in maintaining REM muscle atonia, and a corresponding increase in muscle tone during sleep in those individuals with RBD [99]. Numerous studies have uncovered that PD and RBD share common pathogenesis, such as chronic neural tissue damage and aberrant expressions of microRNAs [100, 101]. Molecular imaging also shows that PD with RBD have lower striatal DA transporter activity within the caudate and putamen comparing to PD without RBD, which might imply DA system is also involved in symptomatic progress of RBD in PD [102]. These findings may explain why the prevalence of RBD in PD patients is so high. In addition, PD patients with co-existent RBD are characterized by older ages, male, younger ages of PD onset, akinetic/rigid phenotype, falls, higher disease severity, longer disease duration, greater motor fluctuations, and higher levodopa dose [21,103]. Meta-analysis also strongly suggests a relationship between RBD and cognitive impairment, making it a sign of worsening condition in PD patients [104].

Clonazepam, a long-acting sedating benzodiazepine, is the first-line treatment options for RBD [105] (Table 3). The specific mechanism of clonazepam is not clear yet, and the evidence of its effectiveness for RBD is based on numerous observational studies [86]. Although there is no enough evidence on reduction of objective or subjective RBD severity, clonazepam can significantly reduce phasic electromyography (EMG) activity on polysomnography [106]. Clonazepam mono-therapy was proved ineffective in the patients, a combination of clonazepam with one or multiple other pharmacological agents, such as melatonin, carbamazepine and pramipexole was reported beneficial [105].

There are not too many studies focusing on treatment effects of melatonin on RBD. Some studies showed 3-12 mg/d melatonin could reduce RBD-related injuries with few side effects, although numbers of RBD events were not reduced [86]. Reports say the pathway that melatonin improves RBD is related to several aspects, such as reducing tonic EMG activity during REM sleep, inhibiting gammaaminobutyric acid, stabilizing the circadian rhythm, increasing striatal L-dopa bioavailability and modulating skeletal muscles [107]. It is suggested that melatonin can be used as a safe add-on treatment option for PD patients with RBD, especially in the elderly. Prolonged-release melatonin 4 mg/d showed not much effect in reducing RBD in PD, but whether other doses are also ineffective is still unclear [108]. Ramelteon is a melatonin receptor agonist, which has a beneficial effect
Taximaimaiti et al. on idiopathic and secondary RBD. One study showed ramelteon could not only improve nighttime sleep but also scores of UPDRS-III, which aroused much interest in its mechanism of improving motor symptoms in PD patients [107].

Rotelgintine is the only dopaminergic agonist that showed RBD symptom improvement currently in PD patients. Its mechanism is still unclear, but seems to be related to improvement in nocturnal motor symptoms [109]. Pramipexole is reported to affect REM sleep by increasing REM sleep latency and decreasing total REM sleep time [74]. In idiopathic RBD patients, pramipexole markedly reduced the frequency and severity of RBD symptoms and maintained efficacy for up to 25 months [110] but in PD patients with RBD, pramipexol showed lack of effects [111].

Cholinesterase inhibitor rivastigmine was used as an alternative treatment in only one study when melatonin and clonazepam were refractory in PD patients with RBD [112]. Rivastigmine showed beneficial effect in reducing RBD events and improving subjective nighttime sleep, suggesting it might be useful in controlling RBD resistant to traditional treatments. But the sample size of related experiments was too small to draw definite conclusions. Memantine can reduce the frequency of dream enactment and decrease total REM sleep time, which is suggested to be suitable to PD patients with dementia and RBD at the same time [113]. Other drugs like sodium oxybate and zopiclone are also effective in RBD treatment, but their efficacy has not been proven in PD [114].

Antipsychotic drugs like clozapine and quetiapine are also proved to be effective for idiopathic RBD patients and psychotic symptoms in PD patients [85]. But there are no related reliable reports about their effects on RBD in PD. Some drugs should be avoided or reduced because they may aggravate or worsen RBD, such as selective serotonin-reuptake inhibitors (SSRI), benzodiazepines, tricyclic antidepressants, barbiturates and monoamine oxidase inhibitors [115].

### 2.4. Excessive Daytime Sleepiness (EDS)

EDS is defined as an inability to maintain wakefulness and alertness during the major waking episodes of the day, which results in uncontrolled sleep or sudden sleep attacks [117]. Approximately one-third of PD patients had EDS [118]. EDS, especially the sudden sleep attacks, posed a great risk to PD patients’ daily lives when driving cars or operating machines, which limited their activities to a very small life circle and significantly increased disease burden [85]. Some studies believe that EDS is a potential risk factor leading to the deterioration of PD [87] Dhawan et al. found EDS was much worse in drug-naive PD patients compared to healthy controls, and became even worse in advanced PD [119]. Although it is often considered to be a complication caused by sleep disturbance at night, some studies suggested that improvement of nocturnal sleep did not modify the daytime sleepiness in PD patients, which pointed out that diurnal sleepiness occurs independently of nocturnal sleep disturbances in PD patients [120].

Pathology of EDS seems to be related to neurodegeneration and extra-nigral pathologic changes [57, 121]. It is also regarded as a marker of widespread neurodegeneration in some studies [57]. Functional imaging studies found PD patients with EDS displayed a trend of increased network connectivity of the posterior default mode network, which was also related to mind-wandering [122]. Many studies have demonstrated that EDS is associated with older age, male, advanced motor impairment, hallucinations, depression, anx-

| Pharmacological treatments of RBD in PD patients. |
|--------------------------------------------------|
| **Sedating benzodiazepine**                      |
| Clonazepam                                       |
| - Recommended Dose                               |
| 0.5-2 mg [105]                                   |
| - Benefits                                       |
| reduce RBD events; improve subjective nighttime sleep; reduce phasic EMG activity |
| - Side Effects                                   |
| worsen OSA; morning sedation; falls; confusion; daytime somnolence |
| **Melatonin and Melatonin agonist**              |
| Melatonin                                        |
| - Recommended Dose                               |
| 3-12 mg [86]                                     |
| - Benefits                                       |
| reduce RBD-related injuries; improve subjective nighttime sleep |
| - Side Effects                                   |
| mild headaches; daytime somnolence; fatigue |
| Ramelteon                                        |
| - Recommended Dose                               |
| 8 mg [107]                                       |
| - Benefits                                       |
| reduce RBD events; improve subjective nighttime sleep; sleep; improve PD motor symptom |
| - Side Effects                                   |
| daytime somnolence; nausea; lightheadedness; delirium; worsen constipation |
| **Dopaminergic agonists**                        |
| Rotigotine                                        |
| - Recommended Dose                               |
| 2-16 mg [116]                                    |
| - Benefits                                       |
| reduce RBD events; improve PD motor and non-motor symptom; reduce pain |
| - Side Effects                                   |
| local site reactions; dyskinesias; headache; dizziness; daytime somnolence; fatigue; nausea |
| **Others**                                       |
| Rivastigmine (patch)                             |
| - Recommended Dose                               |
| 4.6 mg [112]                                     |
| - Benefits                                       |
| reduce RBD events; improve subjective nighttime sleep |
| - Side Effects                                   |
| minor peripheral cholinergic action |
| Memantine                                        |
| - Recommended Dose                               |
| 20 mg [113]                                      |
| - Benefits                                       |
| reduce RBD events; improve cognitive function |
| - Side Effects                                   |
| bradycardia; nausea |
Table 4. Pharmacological treatments of EDS in PD patients.

| Recommended Dose | Benefits | Side Effects |
|------------------|----------|--------------|
| Melatonin        | reduce EDS; improve subjective sleep quality | daytime somnolence; mild headaches; fatigue |
| Istradefylline   | reduce EDS; improving PD motor symptoms | insomnia; psychosis; headache; reduced appetite; nausea |
| Dopaminergic agonists | | |
| Ropinirole immediate-release | reduce EDS; improved subjective quality of sleep | hallucination; dyskinesia; dizziness; daytime somnolence; orthostatic hypotension; leg edema; nausea |
| Ropinirole prolonged-release | reduce EDS; improved subjective quality of sleep | hallucination; dyskinesia; dizziness; daytime somnolence; orthostatic hypotension; leg edema; nausea |
| Sodium oxybate   | reduce EDS; reduce sudden sleep attack; improve subjective and objective of nighttime sleep; reduce fatigue | suppress breathing; induce OSA; induce insomnia; aggravate EDS; rebound morning tremor; dizziness; nocturia; nausea; reduced alertness |
| Modafinil        | 100–200mg [135] | reduce EDS; reduce sudden sleep attack; headache; nausea; dry mouth; anorexia; elevate blood pressure and heart rate |
| Methylphenidate  | 10–80mg [132] | reduce EDS; improve subjective and objective of nighttime sleep |

PD patients should start using methylphenidate 2 weeks after discontinuation of monoamine oxidase inhibitors [125]. Although EDS in PD patients, as well as improve motor and gait symptoms [132]. Methylphenidate can also dramatically reduce EDS in PD patients, which seems to be related to improving nighttime sleep quality [53, 127] (Table 4) but whether they are still effective in PD patients who only have EDS and sleep well at night is still unclear. Modafinil is a widely used wake-promoting agent that can treat daytime somnolence and sudden sleep attack [128]. It can reduce EDS and sudden sleep attack, although objective measures of sleepiness do not alter [129]. It is well tolerated and has a low prevalence of side effects [130] but in older PD patients with severe cardiovascular diseases, use of modafinil should be cautious because it can elevate blood pressure and heart rate. Sodium oxybate can improve EDS and disturb nighttime sleep at the same time. It can significantly enhance subjective and objective sleep quality [131]. Although Sodium oxybate is well tolerated in most people, its negative effect on breathing at night restricts its usage in PD patients. Methylphenidate can also dramatically reduce EDS in PD patients, as well as improve motor and gait symptoms [132]. PD patients should start using methylphenidate 2 weeks after discontinuation of monoamine oxidase inhibitors [125]. Although efficacy of methylphenidate on EDS is better in PD patients, more RCT studies are wanted. Istradefylline, a selective adenosine A2A receptor antagonist, has been reported to improve EDS in PD patients [133]. It can enhance alertness and increase waking hours. Studies showed it had no negative impact on sleep, which made it a good drug [133]. Caffeine is very common in daily refreshing drinks and believed to be useful on daytime sleepiness. But studies have found no significant benefits on EDS in PD patients [134]. There are also some drugs like Atomoxetine that can reduce EDS in PD patients, but we still lack reliable data for that.

2.5. Sleep Disordered Breathing (SDB)

15 to 76% PD patients can suffer from SDB [32]. It is usually divided into obstructive and restrictive pulmonary dysfunction, which includes obstructive sleep apnea (OSA), upper airway obstruction, central sleep apnea, et al. [137]. SDB in PD can also be divided into central, obstructive and mixed, but in most studies, it is not clearly classified [138]. Among various kinds of SDB, OSA is the most common type of breath problem in sleep. OSA is characterized by recurrent partial or complete obstruction of the upper airways during sleep, and it can occur in about 40-60% of PD patients [139]. Clinically, OSA can result in cardiac arrhythmias, nighttime confusion, EDS, refractory hypertension, memory problems and nocturia [137]. While there are also some studies that show PD patients with OSA are less likely to have EDS than non-PD patients with OSA [32]. Timely diagnosing SDB in PD patients and giving proper intervention is of vital importance. Presence of SDB in PD patients can lead to abnormal hypercapnia, resulting in daytime somnolence, fatigue, and cognitive impairment, as well as various cardiovascular, psychiatric and neurologic consequences [57].

The etiology of sleep apnea in PD patients was similar to that of the general population [32]. It has been proposed that pulmonary dysfunction, rigidity of muscles of the chest wall, and changes in posture/kyphoscoliosis may be potential risks for SDB in PD patients [32]. Neurodegeneration was also
proposed as a cause of SDB in PD, but studies showed no correlation between SDB and caudal brainstem serotonergic innervation or striatal dopaminergic innervation [140]. There is also an association between SDB and other types of sleep disorders. For example, OSA can aggravate excessive daytime somnolence in PD patients [141]. In some studies, SDB increases the frequency and severity of RBD events and RBD may render PD patients prone to SDB, although RBD influences sleep-related breathing parameters modestly [142, 143] but in other studies, PD patients with RBD seem to experience lower rate of OSA, which is possibly due to a protective effect of enhanced muscle tone during REM sleep [140].

As for OSA, a meta-analysis has found OSA is associated with increased severity of PD-associated cognitive dysfunction and motor symptoms and may accelerate the neurodegenerative process of PD [139]. High prevalence of OSA in PD patients is also related to many risk factors, such as reduced airway patency regulation, laryngopharyngeal motor dysfunction, autonomic dysfunction, and alterations in motor coordination regulation [144, 145]. Studies have found severe OSA is associated with an obvious reduction in the number of position changes and an increased supine sleep position while sleeping [146]. While in some studies, OSA is related to both the central dysfunction of the brainstem respiratory centers and a peripheral airways involvement [140]. Higher body mass index (BMI) is one of the most important risk factors for OSA in general population. But in PD patients, OSA seems unrelated to the level of BMI and is generally less severe than that of the general population [140]. This may suggest that alteration of the laryngopharyngeal motor control is a distinct mechanism contributing to OSA in PD.

Treatment for SDB in PD was the same as that for the general population. Gold standard treatment of OSA is the continuous positive airway pressure (CPAP) [140]. Long-term use of CPAP can significantly improve subjective and objective sleep quality, as well as daytime sleepiness [147]. Currently, there are very few articles about the effects of pharmacological treatments on SDB, and none of them has shown clear improvement. For example, DA agonists showed an ambiguous impact on SDB [148]. On one hand, DA agonists can reduce SDB severity during REM sleep because of loss of normal muscle atonia; but on the other hand, they seem to enhance the risk of central SDB. Levodopa can improve diaphragm function during acute respiratory failure in patients with COPD, but itself also has a risk of inducing diaphragmatic dyskinesias which may present as marked dyspnoea [138,149]. DBS also does not show significantly impair respiratory drive, but new targets such as the PPN may modify central ventilation control, as PPN directly changes sympathetic activity [150]. Other treatment options include positional therapy to promote sleep in a non-supine position, custom-made mandibular advancement devices, optimization of nasal breathing, etc. [140].

3. NON-PHARMACOLOGICAL TREATMENTS

3.1. Sleep Hygiene Education

Sleep hygiene education is the first step to manage sleep disorders in PD patients. Its purpose is to help patients establish healthy sleep habits to improve sleep quality. Many PD patients do not have proper sleep hygiene habits. Some may self-medicate with alcohol to induce sleep, and some go to bed too early and watch TV or play with their phone in bed, which will surely affect the establishment of normal sleep. Exposure to caffeine, alcohol, tea or nicotine less than 4 h before going to bed will also result in poor sleep quality [5]. To improve the sleep-wake cycle and consolidate the effect of pharmacological treatments, it is necessary to maintain regular sleep patterns, increase daytime outdoor activity, limit daytime napping, and avoid prolonged bed rest during non-sleeping hours.

3.2. Exercise

Regular exercise is recommended in PD patients. A meta-analysis including a total of 690 PD patients found exercise had a significant positive effect on subjective sleep quality [151]. Types of exercise should be suitable to patients’ disease severity, economic status, personal acceptance and convenience. Generally speaking, exercise can be divided into rehabilitation training under the guidance of doctors or professionals, and general mass sports. Rehabilitation training is more targeted and safer. It can simultaneously implement rehabilitation treatment for sleep disorders, motor and non-motor functions. For example, progressive resistance training can improve insomnia and muscle strength in moderate PD at the same time [152]. There is also a report about benefits of multidisciplinary intensive rehabilitation treatment (MIRT) on sleep disorders in PD, which included a wide range of exercises such as aerobic exercises, relaxation techniques, stretching, stabilometric platform exercises focusing on balance and gait, occupational therapy, speech therapy, hydrotherapy, and robotic-assisted walking training [153]. PD who underwent MIRT showed significant improvement in overall sleep quality comparing to those kept on pharmacologic therapy only without rehabilitation. Slow, smooth movements like Baduanjin Qigong and Tai Chi have proved to improve gait performance and functional mobility in elderly PD patients [154,155]. They can be practiced at home, ensuring the continuity and convenience of treatment. However, research on exercise to improve sleep disorders in PD patients is still very limited, and the exercise modality, frequency, duration, and intensity needed for optimization of sleep is not known [156].

3.3. Deep Brain Stimulation

Numerous pieces of evidence have shown deep brain stimulation (DBS) can improve sleep quality in PD patients[57]. DBS improves sleep-wake disturbances, partly by its direct circuit-mediated effect and partly by an indirect effect such as the resolution of nocturnal motor complications and a reduction of dopaminergic medication [157]. The most commonly used DBS surgeries are bilateral subthalamic nucleus (STN) DBS and pallidal (GPi) DBS. Studies show bilateral STN-DBS surgery can improve RLS symptoms and QOL in PD patients, and these kinds of changes are independent of depression and dopaminergic medication [158, 159]. Although STN-DBS significantly improved subjective sleep parameters in over-1-year follow-up, it could not improve objective sleep parameters like sleep efficiency or sleep architecture [160]. When comparing non-motor effects
of STN-DBS and GPi-DBS, both of them can improve sleep quality, fatigue, mood, and cognition, but only STN-DBS can reduce pain and improve memory and only GPi-DBS are good for cardiovascular and sexual function domains [161]. But DBS surgery can also induce unexpected sleep disorders. For example, some studies found that although bilateral STN-DBS could improve the subjective sleep quality, and EDS might be induced or worsen [162]. Studies also reported an increase of complex behavior during REM and changes in REM sleep duration after STN-DBS or GPi-DBS surgery, which can eventually evolve into RBD events [163].

Some studies also recommend DBS of the PPN as a potential surgery to improve sleep disorders in PD patients [164]. Although PPN-DBS is primarily used to improve gait freezing and postural instability in PD and primary progressive freezing of gait (PPFG), it also shows a modulation effect on some non-motor functions, including REM sleep, mood, attention, arousal, sleep-wake cycle and cognition [164-167]. Recent studies have demonstrated PPN is involved in sleep–wake state-dependent central breathing regulation through cholinergic projections to the retrotrapezoid nucleus, which indicates PPN as a potential target for improving SDB in PD patients [168,169]. However, there are also some studies that suggest PPN-DBS may contribute to REM sleep atonia and aggravate RBD in PD patients [165]. In view of the fact that there are too few studies on PPN-DBS to improve sleep disorders in PD, the relevant conclusions need further research.

3.4. Cognitive Behavior Therapy

Cognitive behavior therapy (CBT) is also a good choice for treating sleep disorders in PD. It usually refers to short talking therapy (6 to 12 weeks) helping patients to discover their own problems and establish adaptive behaviors through face-to-face or online [170]. CBT usually includes a combination of sleep hygiene education, stimulus control, relaxation training, and sleep restriction [171]. It commonly performs in a group setting and requires patients to give annual feedbacks [172].

Timed light therapy and bright light therapy are the most commonly-used CBT in the clinic. They are effective in restoring the sleep-wake cycles by exposing to lights regularly as well as increasing melatonin secretion through a rebound effect [173,174]. Studies have found that CBT is useful in alleviating insomnia, EDS, RBD in PD patients, and it is well tolerated and well received by patients [175]. After several rounds of CBT treatment, although objective sleep measured by actigraph did not improve, most patients still reported an improvement of subjective sleep quality [176]. Side effects are often rare and mostly controllable. For example, falling asleep during light therapy should be avoided because it may burn patient’s face [51]. CBT is a safe and efficacious treatment, but current studies all show a high drop-out rate. Strategies to increase convenience and enhance treatment effect in PD patients are expected.

3.5 Complementary Therapies

In addition to the afore-mentioned treatment methods, some non-pharmacological treatments have also shown certain therapeutic effects in clinical observations. For instance, massaging the leg and the application of a heat pack received good results in relieving RLS, but the effective time did not seem to be as long as expected [177]. For those with RBD, protective strategies like placing mattresses on the floor or securing windows should be considered because they can help to improve bedroom safety and avoid injuries to both patients and their partners [85, 177]. Psychoeducation, tactile touch and theatre training also showed benefits to sleep quality improvement in PD patients, but relevant researches still lacked strong credibility evidence [178-181].

4. DISCUSSION

Sleep disorders in PD patients sometimes appear alone and sometimes exist in several types at the same time. For example, PD patients with RLS are more likely to develop EDS, while PD dementia patients are more likely to have both EDS and RBD [57]. Different sleep disorders can also affect each other. For example, RBD can reduce the severity of OSA, but they will jointly aggravate the cognitive impairment of PD [182]. In addition to the sleep disorders mentioned above, nocturia and circadian rhythm disorders are also very common clinically, and the treatments basically overlap with the above [123]. What’s more, management of comorbid psychiatric symptoms and emotional disorders is also very important to improve sleep quality. Studies have shown that treatment of overnight hallucination, delusion and confusion may consolidate the effectiveness of sleep therapy [183].

When dealing with sleep disorders in PD patients, the following points should be noted:

1. Management of sleep disorders in PD patients should start with sleep hygiene education to help patients establish good sleep habits.
2. Pharmacological treatments of sleep disorders should start with the optimization of antiparkinsonian therapy, especially alternations of dopaminergic agents, to optimize overnight motor and non-motor symptoms.
3. Drugs which can cause or worsen sleep disorders should be withdrawn or replaced.
4. When selecting antidepressants or antipsychotics, those that are effective to both sleep disorders and comorbid emotional disorders or psychiatric symptoms should be chosen.
5. Pharmacological and non-pharmacological treatments can be used alone or at the same time.
6. Treatment convenience and patients’ economic condition should be taken into account to have a stable and long-term effect.

Treating sleep disorders in PD patients is a long and iterative process. Supports from family and society are also very important to build up patients’ confidence and maintain emotional stability. Improving the sleep problems of PD patients at night can not only improve the QOL of the patients themselves but also reduce the burden on caregivers [184]. Therefore, sleep disorders in PD patients should be identified, diagnosed and intervened as early as possible.
CONCLUSION

Sleep disorders have a high prevalence in PD patients. The most cited sleep disorders in PD included insomnia, RLS, RBD, EDS and SDB, which sometimes appear alone and sometimes exist in several types at the same time. In this review, we discussed some recommended pharmacological and non-pharmacological treatments for sleep disorders in PD. We listed the recommended dosages, benefits and side effect of related drugs, as well as non-pharmacological interventions, including sleep hygiene education, exercise, deep brain stimulation, cognitive behavior therapy and complementary therapies. Management of sleep disorders in PD is a long and iterative process. It is necessary to choose the most suitable treatment with the least side effects in order to have a stable and long-term effect.

LIST OF ABBREVIATIONS

| Abbreviation | Description |
|--------------|-------------|
| BG           | Basal ganglia |
| BMI          | Body mass index |
| CBT          | Cognitive behavior therapy |
| CPAP         | Continuous positive airway pressure |
| DA           | Dopamine |
| DBS          | Deep brain stimulation |
| EDS          | Excessive daytime sleepiness |
| EMG          | Electromyography |
| ESS          | Epworth Sleepiness Scale |
| GPi          | Pallidal |
| ICD          | Impulse control disorders |
| LCIG         | Levodopa-carbidopa intestinal gel |
| MIRT         | Multidisciplinary intensive rehabilitation treatment |
| OSA          | Obstructive sleep apnea |
| PD           | Parkinson's disease |
| PDSS         | Parkinson's Disease Sleep Scale |
| PPN          | Primary progressive freezing of gait |
| PPFN         | Pedunculopontine nucleus |
| PSQI         | Pittsburgh Sleep Quality Index |
| QOL          | Quality of life |
| RBD          | Rapid eye movement sleep behavior disorders |
| REM          | Rapid eye movement |
| RLS          | Restless legs syndrome |
| SDB          | Sleep disordered breathing |
| SN           | Substantia nigra |
| SSS          | Stanford sleepiness scale |
| STN          | Subthalamic nucleus |
| SWS          | Slow wave sleep |
| UPDRS        | Unified Parkinson's Disease Rating Scale |

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

This work was funded by the National Nature Science Foundation of China (81671251).

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

[1] Murueta-Goyena, A.; Andikoetxea, A.; Gómez-Esteban, J.C.; Gabilondo, I. Contribution of the gabaergic system to non-motor manifestations in premotor and early stages of Parkinson’s Disease. Front. Pharmacol., 2019, 10, 1294. http://dx.doi.org/10.3389/fphar.2019.01294 PMID: 31736763

[2] Xie, C.; Zhu, M.; Hu, Y. Risk stratification for REM sleep behavior disorder in patients with Parkinson’s disease: A PRISMA-compliant meta-analysis and systematic review. Clin. Neurol. Neurosurg., 2021, 202, 106484-106484. http://dx.doi.org/10.1016/j.clineuro.2021.106484 PMID: 33556851

[3] Chaudhuri, K.R.; Martinez-Martin, P.; Schapira, A.H.V.; Stocchi, F.; Sethi, K.; Odin, P.; Brown, R.G.; Koller, W.; Barone, P.; MacPhee, G.; Kelly, L.; Rabey, M.; MacMahon, D.; Thomas, S.; Ondo, W.; Rye, D.; Forbes, A.; Tluk, S.; Dhawan, V.; Bowron, A.; Williams, A.J.; Olanow, C.W. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: The NMSQuest study. Mov. Disord., 2006, 21(7), 916-923. http://dx.doi.org/10.1002/mds.20844 PMID: 16547944

[4] Park, S.; Kim, R.; Shin, J.H.; Kim, H.J.; Pack, S.H.; Jeon, B. The probable REM sleep behavior disorder negatively affects health-related quality of life in Parkinson’s disease with bilateral subthalamic nucleus stimulation. Parkinsonism Relat. Disord., 2020, 81, 136-139. http://dx.doi.org/10.1016/j.parkreldis.2020.06.031 PMID: 33129010

[5] Voysey, Z.J.; Barker, R.A.; Lazar, A.S. The treatment of sleep dysfunction in neurodegenerative disorders. Neurotherapeutics, 2021, 18(1),202-216. PMID: 33179197

[6] Frandsen, R.; Asah, C.; IbSEN, R.; Kjellberg, J.; Jennum, P.J. Health, social, and economic consequences of rapid eye movement sleep behavior disorder: A controlled national study evaluating societal effects. Sleep (Basel), 2021, 44(2), zsa162. http://dx.doi.org/10.1093/sleep/zsa162 PMID: 32842411

[7] Kalaitzakis, M.E.; Gentleman, S.M.; Pearce, R.K.B. Disturbed sleep in Parkinson’s disease: Anatomical and pathological correlates. Neuropathol. Appl. Neurobiol., 2013, 39(6), 644-653. http://dx.doi.org/10.1111/nan.12024 PMID: 23363035

[8] Monti, J.M.; Monti, D. The involvement of dopamine in the modulation of sleep and waking. Sleep Med. Rev., 2007, 11(2), 113-133. http://dx.doi.org/10.1016/j.smrv.2006.08.003 PMID: 17275369
Treatments of Sleep Disorders in PD

Current Neuropharmacology, 2021, Vol. 19, No. 12 2243

[10] Saper, C.B.; Chou, T.C.; Scammell, T.E. The sleep switch: Hypothalamic control of sleep and wakefulness. Trends Neurosci., 2001, 24(12), 726-731. http://dx.doi.org/10.1016/S0166-2236(00)00206-2 PMID: 11718878

[11] Vetrivelan, R.; Qiu, M.-H.; Chang, C.; Lu, J. Role of Basal Ganglia in sleep-wake regulation: Neural circuitry and clinical significance. Front. Neuroanat., 2010, 4, 145. http://dx.doi.org/10.3389/fnana.2010.00145 PMID: 21151379

[12] Smith, A.D.; Olson, R.J.; Justice, J.B., Jr. Quantitative microdialysis of dopamine in the striatum: Effect of circadian variation. J. Neurosci. Methods, 1992, 44(1), 33-41. http://dx.doi.org/10.1016/0165-0270(92)90111-P PMID: 1279321

[13] Herrera-Sole, A.; Cuesta-Morales, W.; Nunez-Jaramillo, L.; Arias-Carrion, O. Dopaminergic modulation of sleep-wake states. CNS Neurol. Disord. Drug Targets, 2017, 16(4), 380-386. http://dx.doi.org/10.2174/1871527316661170320145429 PMID: 28322171

[14] Benazzouz, A.; Mamad, O.; Abedi, P.; Bouali-Benazzouz, R.; Chétrit, J. Involvement of dopamine loss in extrastriatal basal ganglia nuclei in the pathophysiology of Parkinson’s disease. Front. Aging Neurosci., 2014, 6, 87. http://dx.doi.org/10.3389/fnagi.2014.00087 PMID: 24860498

[15] Gros, P.; Vidovic, A. Overview of sleep and circadian rhythm disorders in Parkinson disease. Clin. Geriatr. Med., 2020, 36(1), 119-130. http://dx.doi.org/10.1016/j.cger.2019.09.005 PMID: 31733692

[16] Heenan, A.; Pipe, A.; Lemay, K.; Davidson, J.R.; Tulloch, H. Cognitive-behavioral therapy for insomnia tailored to patients with cardiovascular disease: A pre-post study. Behav. Sleep Med., 2020, 18(3), 372-385. http://dx.doi.org/10.1080/15402002.2019.1594815 PMID: 31007057

[17] Jongwasanisri, P.; Prayoonwivat, N.; Pisampong, A.; Srivianitchaipoon, P.; Chotinawattarakul, W. Evaluation of sleep disorders in Parkinson’s disease: A comparison between, physician diagnosis and self-administered questionnaires. J. Med. Assoc. Thai., 2014, 97(3), S68-S77. PMID: 24772582

[18] Tholfsen, L.K.; Larsen, J.P.; Schulz, J.; Tysnes, O-B.; Gjerstad, K.L.; Hundemer, H.P.; Lledó, A.; Wood, A.; Frewer, P.; Schwarz, J. Pergolide versus levodopa monotherapy in early Parkinson’s disease. Acta Neurol. Scand., 2006, 113(1), 18-24. http://dx.doi.org/10.1111/j.1600-4045.2005.00514.x PMID: 16367984

[19] Oertel, W.H.; Wolters, E.; Sampaio, C.; Gimenez-Roldan, S.; Bergamasco, B.; Dujardin, M.; Grosset, D.G.; Arnold, G.; Leenders, K.L.; Hunderme, H.P.; Lledó, A.; Wood, A.; Frewer, P.; Schwarz, J. Pergolide versus levodopa monotherapy in early Parkinson’s disease: Patients the placebo study. Mov. Disord., 2006, 21(3), 343-353. http://dx.doi.org/10.1002/mds.20724 PMID: 16211594

[20] Magyar, K.; Szende, B. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. Neurotoxicology, 2004, 25(1-2), 233-242. http://dx.doi.org/10.1016/S0161-811X(03)00112-5 PMID: 14697988

[21] Solis-García del Pozo, J.; Mínguez-Mínguez, S.; de Groot, P.W.J.; Jordán, J. Rasagiline meta-analysis: A spotlight on clinical safety and adverse event profile in Parkinson’s disease. Expert Opin. Drug Saf., 2013, 12(4), 479-486. http://dx.doi.org/10.1517/14744422.2013.790956 PMID: 23634791

[22] Larsen, J.P.; Worm-Petersen, J.; Sidén, A.; Gordin, A.; Reini-kainen, K.; Leinonen, M. The tolerability and efficacy of entacpene over 3 years in patients with Parkinson’s disease. Eur. J. Neurol., 2003, 10(2), 137-146. http://dx.doi.org/10.1046/j.1468-1331.2003.00559.x PMID: 12602288

[23] Wallace, D.M.; Wohlgemuth, W.K.; Trott, L.M.; Amara, A.W.; Malaty, I.A.; Factor, S.A.; Nallu, S.; Wittine, L.; Hauser, R.A. Practical evaluation and management of insomnia in Parkinson’s disease: A review. Mov. Disord. Clin. Pract. (Hoboken), 2020, 7(3), 250-266. http://dx.doi.org/10.1002/mdc3.12899 PMID: 32258222

[24] Zhu, K.; van Hilten, J.J.; Marinus, J. The course of insomnia in Parkinson’s disease. Parkinsonism Relat. Disord., 2016, 33, 51-57. http://dx.doi.org/10.1016/j.parkreldis.2016.09.010 PMID: 27639814

[25] Chahine, L.M.; Amara, A.W.; Vidovic, A. A systematic review of the literature on disorders of sleep and wakefulness in Parkinson’s disease from 2005 to 2015. Sleep Med. Rev., 2017, 35, 33-50. http://dx.doi.org/10.1016/j.spmrv.2016.08.001 PMID: 27863901

[26] Wailke, S.; Herzog, J.; Witt, K.; Deuschl, G.; Volkmann, J. Effect of controlled-release levodopa on the microstructure of sleep in Parkinson’s disease. Eur. J. Neurol., 2011, 18(4), 590-596. http://dx.doi.org/10.1111/j.1468-1331.2010.03213.x PMID: 20849470

[27] Palha, R.; Stacy, M.A.; Factor, S.A.; Lyons, K.E.; Stocchi, F.; Fehligh, B.P.; Elmer, L.W.; Truong, D.D.; Earl, N.L.; Study, E.P.A. Randomised controlled study in advanced Parkinson disease. Neurology, 2007, 68(14), 1108-1115. http://dx.doi.org/10.1212/01.wnl.0000258660.74391.c1 PMID: 17404192

[28] Poeae, W.H.; Rascol, O.; Quinn, N.; Tolosa, E.; Oertel, W.H.; Marottignon, E.; Rupp, M.; Boroojerdi, B.; Investigators, S.P. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: A double-blind, double-dummy, randomised controlled trial. Lancet Neurol., 2007, 6(6), 513-520. http://dx.doi.org/10.1016/S1474-4422(07)70108-4 PMID: 17509486

[29] Monti, J.M.; Jants, H. The roles of dopamine and serotonin, and of their receptors, in regulating sleep and waking. Prog. Brain Res., 2008, 172, 625-646. http://dx.doi.org/10.1016/S0079-6123(08)00929-1 PMID: 18772053

[30] Qu, W-M.; Xu, X-H.; Yan, M-M.; Wang, Y-Q.; Urade, Y.; Huang, Z-L. Essential role of dopamine D2 receptor in the maintenance of wakefulness, but not in homeostatic regulation of sleep, in mice. J. Neurosci., 2010, 30(12), 4382-4389. http://dx.doi.org/10.1523/JNEUROSCI.4936-09.2010 PMID: 20353474
Juri, C.; Chaná, P.; Tapia, J.; Kunstmann, C.; Parrao, T. Quetiapine for insomnia in Parkinson's disease: Results from an open-label trial. *Clin. Pharmacol.*, 2005, 28(4), 185-187. [http://dx.doi.org/10.1097/01.clp.0000174932.82134.e2 PMID: 16062098]

Seppi, K.; Ray Chaudhuri, K.; Coelho, M.; Fox, S.H.; Katzenschlag, R.; Perez Lloret, S.; Weintraub, D.; Sampaio, C.; Chahine, L.; Hametner, E-M.; Heim, B.; Lim, S-Y.; Poeoe, W.; Djamshidian-Tehrani, A. Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence-based medicine review. *Mov. Disord.*, 2019, 34(2), 180-198. [http://dx.doi.org/10.1002/mds.27602 PMID: 30653247]

Goldman, J.G.; Holden, S. Treatment of psychosis and dementia in Parkinson's disease. *Curr. Treat. Options Neurol.*, 2014, 16(3), 281. [http://dx.doi.org/10.1007/s11940-013-0281-2 PMID: 24466238]

Juncos, J.L.; Roberts, V.J.; Evat, M.L.; Jewart, R.D.; Wood, C.D.; Potter, L.S.; Jou, H.C.; Yeung, P.P. Quetiapine improves psychotic symptoms and cognition in Parkinson’s disease. *Mov. Disord.*, 2004, 19(1), 29-35.

Lebrun, C.; Gely-Nargeot, M-C.; Rossignol, A.; Geny, C.; Bayard, C.; Gély-Nargeot, M-C.; Rossignol, A.; Geny, C.; Bayard, S. Efficacy of cognitive behavioral therapy for insomnia comorbid to Parkinson's disease: A focus on psychological and daytime functioning with a single-case design with multiple baselines. *J. Clin. Psychol.*, 2020, 76(3), 356-376. [http://dx.doi.org/10.1002/jclp.22883 PMID: 31746468]

Medeiros, C.A.; Carvalheiro de Bruijn, P.F.; Lopes, L.A.; Dowling, G.A.; Mastick, J.; Colling, E.; Carter, J.H.; Singer, C.M.; Djamshidian-Tehrani, A. Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence-based medicine review. *Mov. Disord.*, 2019, 34(2), 180-198. [http://dx.doi.org/10.1002/mds.27602 PMID: 30653247]

Goldman, J.G.; Holden, S. Treatment of psychosis and dementia in Parkinson's disease. *Curr. Treat. Options Neurol.*, 2014, 16(3), 281. [http://dx.doi.org/10.1007/s11940-013-0281-2 PMID: 24466238]

Juncos, J.L.; Roberts, V.J.; Evat, M.L.; Jewart, R.D.; Wood, C.D.; Potter, L.S.; Jou, H.C.; Yeung, P.P. Quetiapine improves psychotic symptoms and cognition in Parkinson’s disease. *Mov. Disord.*, 2004, 19(1), 29-35.

Lebrun, C.; Gely-Nargeot, M-C.; Rossignol, A.; Geny, C.; Bayard, S. Efficacy of cognitive behavioral therapy for insomnia comorbid to Parkinson's disease: A focus on psychological and daytime functioning with a single-case design with multiple baselines. *J. Clin. Psychol.*, 2020, 76(3), 356-376. [http://dx.doi.org/10.1002/jclp.22883 PMID: 31746468]

Medeiros, C.A.; Carvalheiro de Bruijn, P.F.; Lopes, L.A.; Dowling, G.A.; Mastick, J.; Colling, E.; Carter, J.H.; Singer, C.M.; Djamshidian-Tehrani, A. Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence-based medicine review. *Mov. Disord.*, 2019, 34(2), 180-198. [http://dx.doi.org/10.1002/mds.27602 PMID: 30653247]
eye movement sleep patterns in rapid eye movement sleep behavior disorder. *Sleep Med.*, 2013, 14(5), 399-406. http://dx.doi.org/10.1016/j.spmem.2013.01.007 PMID: 23490738

Kashihara, K.; Nomura, T.; Maeda, T.; Tsuibo, Y.; Mishima, T.; Takigawa, H.; Nakashima, K. Beneficial effects of ramelteon on rapid eye movement sleep behavior disorder associated with Parkinson's disease: results of a multicenter open trial. *Intern. Med.*, 2016, 55(3), 231-236. http://dx.doi.org/10.2169/internalmedicine.55.5464 PMID: 26831015

Gilian, M.; Coeytaux Jackson, A.; Marshall, N.S.; Hammond, D.; Mullins, A.E.; Hall, J.M.; Bang, B.A.M.; Yee, B.J.; Wong, K.K.H.; Grunstein, R.R.; Lewis, S.J.G. Melatonin for rapid eye movement sleep behavior disorder in Parkinson's disease: A randomised controlled trial. *Mov. Disord.*, 2020, 35(2), 344-349. http://dx.doi.org/10.1002/mds.27886 PMID: 31674060

Trenkwalder, C.; Kies, B.; Rudzinska, M.; Fine, J.; Nilk, J.; Honczarenko, K.; Dioszeghy, P.; Hill, D.; Anderson, T.; Myllyva, V.; Kassubek, J.; Steiger, M.; Zucconi, M.; Tolosa, E.; Poeoe, W.; Surmann, E.; Whitesides, J.; Boroojerdi, B.; Chaudhuri, K.R.; Grp, R.; Rognon, K.N. Sleep on early morning function and sleep in Parkinson's disease: A double-blind, randomized, placebo-controlled study (recovery). *Mov. Disord.*, 2011, 26(1), 90-99. http://dx.doi.org/10.1002/mds.23441 PMID: 21322021

Schmidt, M.H.; Koshal, V.B.; Schmidt, H.S. Use of pramipexole in REM sleep behavior disorder: Results from a case series. *Sleep Med.*, 2006, 7(5), 418-423. http://dx.doi.org/10.1016/j.sleep.2006.03.018 PMID: 16817551

Franzo, L.; Kunmu, H.; Santamaria, J.; Tolosa, E.; Valdideiroila, F.; Marti, M. Lack of effect of pramipexol on REM sleep behavior disorder (RBD) in subjects with Parkinson disease. *Sleep*, 2005, 28, A260-A260.

Di Giacopo, R.; Fasano, A.; Quaranta, D.; Della Marca, G.; Bove, F.; Bentivoglio, A.R. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. *Mov. Disord.*, 2012, 27(4), 559-568. http://dx.doi.org/10.1002/mds.24909 PMID: 22290743

Larsson, V.; Aarsland, D.; Ballard, C.; Minthon, L.; Londos, E. The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. *Int. J. Geriatr. Psychiatry*, 2010, 25(10), 1030-1038. http://dx.doi.org/10.1002/gps.2506 PMID: 20872929

Petersen, K.R.; Storandt, M. Drug treatment of REM sleep behavior disorder: The use of drug therapies other than clonazepam. *J. Clin. Sleep Med.*, 2009, 5(3), 235-239. http://dx.doi.org/10.5664/jcsm.27492 PMID: 19960644

St Louis, E.K.; Boeve, A.R.; Boeve, B.F. REM sleep behavior disorder in Parkinson's disease and other synucleinopathies. *Mov. Disord.*, 2017, 32(5), 645-658. http://dx.doi.org/10.1002/mds.27018 PMID: 28513079

Wang, Y.; Yang, Y.; Wu, H.; Lan, D.; Chen, Y.; Zhao, Z. Effects of rotigotine on REM sleep behavior disorder in Parkinson disease. *J. Clin. Sleep Med.*, 2016, 12(10), 1403-1409. http://dx.doi.org/10.5664/jcsm.6200 PMID: 27568909

Zhu, K.; van Hilten, J.J.; Marinus, J. Course and risk factors for excessive daytime sleepiness in Parkinson's disease. *Parkinsonism Relat. Disord.*, 2016, 24, 34-40. http://dx.doi.org/10.1016/j.parkreldis.2015.10.012 PMID: 26846609

Feng, F.; Cai, Y.; Hou, Y.; Ou, R.; Jiang, Z.; Shang, H. Excessive daytime sleepiness in Parkinson’s disease: A systematic review and meta-analysis. *Parkinsonism Relat. Disord.*, 2021, 85, 133-140. http://dx.doi.org/10.1016/j.parkreldis.2021.02.016 PMID: 33637423

Dhawan, V.; Dhoat, S.; Williams, A.J.; Dimarco, A.; Pal, S.; Forbes, A.; Tobias, A.; Martinez-Martin, P.; Chaudhuri, K.R. The range and nature of sleep dysfunction in untreated Parkinson's disease (PD). A comparative controlled clinical study using the Parkinson's disease sleep scale and selective polysomnography. *J. Neurol. Sci.*, 2006, 248(1-2), 158-162. http://dx.doi.org/10.1016/j.jns.2006.05.004 PMID: 16780888

Ligurio, C.; Mercuri, N.B.; Albanese, M.; Olivola, E.; Stefani, A.; Pierantozzi, M. Daytime sleepiness may be an independent symp-
of excessive sleepiness. J.M.; Arora, S. Evaluation of the safety of modafinil for treatment of excessive sleepiness in Parkinson’s disease: Double blind, placebo trial. Mov. Disord., 2018, 23(12), 1636-1639.

Büchele, F.; Hackius, M.; Schreglmann, S.R.; Omlor, W.; Dusko, P.; Buskova, J.; Ržezka, E.; Majerová, V.; Srp, A.; Jech, R.; Roth, J.; Sonka, K. Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease. Clin. Neuropharmacol., 2010, 33(4), 186-190.

Shen, Y.; Huang, J-Y.; Li, J.; Liu, C-F. Excessive daytime sleepiness and its impact on quality of life in de novo Parkinson’s disease. Neurology, 2019, 40(6), 1151-1156.

Junho, B.T.; Kummer, A.; Cardoso, F.; Teixeira, A.L.; Rocha, N.P. Clinical predictors of excessive daytime sleepiness in patients with Parkinson’s disease. J. Neurol. Clin. Neurophysiol., 2018, 14(4), 530-536.

Dusko, P.; Buskova, J.; Ržezka, E.; Majerová, V.; Srp, A.; Jech, R.; Roth, J.; Sonka, K. Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease. Clin. Neuropharmacol., 2010, 33(4), 186-190.

Shen, Y.; Huang, J-Y.; Li, J.; Liu, C-F. Excessive daytime sleepiness in patients with Parkinson’s disease: Clinical implications and management. Chin. Med. J. (Engl.), 2018, 131(8), 974-981.

Ono, W.G.; Fayle, R.; Atassi, F.; Jankovic, J. Modafinil for daytime somnolence in Parkinson’s disease: Double blind, placebo controlled parallel trial. J. Neurol. Neurosurg. Psychiatry, 2005, 76(12), 1636-1639.

Roth, T.; Schwartz, J.R.L.; Hirshkowitz, M.; Erman, M.K.; Dayno, J.M.; Arora, S. Evaluation of the safety of modafinil for treatment of excessive sleepiness. J. Clin. Sleep Med., 2007, 3(6), 595-602.

Büchele, F.; Hackius, M.; Schreglmann, S.R.; Omlor, W.; Wirth, E.; Marie, A.; Imbach, L.L.; Hägele-Link, S.; Waldvogel, D.; Baumann, C.R.; Schönherr, R.J. Cognition in Parkinson’s disease and sleep disturbance in Parkinson disease: A randomized clinical trial. JAMA Neurology, 2018, 75(1), 11-18.

Devos, D.; Krystkowiak, P.; Clement, F.; Dujardin, K.; Cottencin, O.; Wauquier, N.; Aebi, M.; Thielen, B.; Kroumova, M.; Duhamel, A.; Destée, A.; Boret, R.; Defebvre, L. Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry, 2007. 78(5), 470-475.

Suzuki, K.; Miyamoto, M.; Miyamoto, T.; Uchiyama, T.; Watanabe, Y.; Suzuki, S.; Kadowaki, T.; Fujita, H.; Matsubara, T.; Sakuramoto, H.; Hirata, K. Istrafedrine improves daytime sleepiness in patients with Parkinson’s disease: An open-label, 3-month study. J. Neurol. Sci., 2017, 380, 230-233.

Postuma, R.B.; Lang, A.E.; Munhoz, R.P.; Charland, K.; Pelletier, A.; Moschovik, M.; Filla, L.; Zanatta, D.; Rios Romenets, S.; Altman, R.; Chiang, R.; Shah, B. Caffeine for treatment of Parkinson disease: A randomized controlled trial. Neurology, 2012, 79(7), 651-658.

Högl, B.; Saletu, M.; Brandauer, E.; Glatzl, S.; Frauscher, B.; Seppi, K.; Ulmer, H.; Wenning, G.; Poewe, W. Modafinil for the treatment of daytime sleepiness in Parkinson’s disease: A double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep, 2002, 25(8), 905-909.

Mao, L.Q.R.; Wen, M-M.; Ng, K.K.; Cheung, J.H.M.; Lee, W.; Xu, Z.; Hartono, S.; Tan, E.K.; Chan, L.L.; Tan, L.C-S. Increased activation of default mode network in Early Parkinson’s with excessive daytime sleepiness. Front. Neurosci., 2020, 13, 14.

Mantovani, S.; Smith, S.S.; Gordon, R.; O’Sullivan, J.D. An overview of sleep and circadian dysfunction in Parkinson’s disease. J. Sleep Res., 2018, 27(3), e12673. PMID: 29493044

Goldman, J.G.; Stebbins, G.T.; Leung, V.; Tilley, B.C.; Goetz, C.G. Relationships among cognitive impairment, sleep, and fatigue in Parkinson’s disease using the MDS-UPDRS. Parkinsonism Relat. Disord., 2014, 20(11), 1135-1139.

http://dx.doi.org/10.1016/j.parkreldis.2014.08.001 PMID: 25150770

Yun, S-W.; Kim, J-S.; Oh, Y-S.; Ryu, D-W.; Lee, K-S. Excessive daytime sleepiness and its impact on quality of life in de novo Parkinson’s disease. Ann. Intern. Med., 2020, 6(4), 00165-2020. PMID: 33043046

Elfil, M.; Bahbhab, E.I.; Attia, M.M.; Eldokmak, M.; Koo, B.B. Impact of obstructive sleep apnea on cognitive and motor functions in Parkinson’s disease. Mov. Disord., 2021, 36(3), 570-580. PMID: 33296545

Herrmann, W.; Schmitz-Peiffer, H.; Kasper, E.; Fauser, M.; Franke, C.; Wienecke, M.; Otto, K.; Löhle, M.; Brandt, M.D.; Reichmann, H.; Storch, A. Sleep disturbances and sleep-disordered breathing impair cognitive performance in Parkinson’s Disease. Front. Neurosci., 2020, 14, 689.

D’Arrigo, A.; Floro, S.; Barnesagi, F.; Casellato, C.; Sferazza Papa, G.F.; Centanni, S.; Priori, A.; Bocci, T. Respiratory dysfunction in Parkinson’s disease: A narrative review. EJR Open Res., 2020, 6(4), 00165-2020. PMID: 33043046
A quantitative analysis of the effect of bilateral subthalamic stimulation on sleep in patients with Parkinson’s disease. *Clin. Neurol. Neurosurg.*, 2020, 192, 105721.

http://dx.doi.org/10.1016/j.clineuro.2020.105721 PMID: 32058203

Cavalloni, F.; Debove, I.; Lachennayer, M.L.; Krack, P.; Pollo, C.; Schuepbach, W.M.M.; Bassetti, C.L.A.; Bargiota, P. A case series and systematic review of rapid eye movement sleep behavior disorder outcome after deep brain stimulation in Parkinson’s disease. *Sleep Med.*, 2021, 77, 170-176.

http://dx.doi.org/10.1016/j.sleep.2020.11.025 PMID: 33412362

Ricciardi, L.; Sarchioto, M.; Morgante, F. Role of pedunculopontine nucleus in sleep-wake cycle and cognition in humans: A systematic review of DBS studies. *Neurobiol. Dis.*, 2019, 128, 53-58.

http://dx.doi.org/10.1016/j.nbd.2019.01.022 PMID: 30710676

Chambers, N.E.; Lanza, K.; Bishop, C. Pedunculopontine nucleus degeneration contributes to both motor and non-motor symptoms of Parkinson’s disease. *Front. Pharmacol.*, 2020, 10, 1494.

http://dx.doi.org/10.3389/fphar.2019.01494 PMID: 32009944

Pereira, E.A.; Muthusamy, K.A.; De Pennington, N.; Joint, C.A.; Aziz, T.Z. Deep brain stimulation of the pedunculopontine nucleus in Parkinson’s disease. Preliminary experience at Oxford. *Br. J. Neurosurg.*, 2008 (Suppl. 1), S41-S44.

http://dx.doi.org/10.1080/02688690802448335 PMID: 19085352

Stefani, A.; Lozano, A.M.; Pellep, A.; Stanzione, P.; Galati, S.; Tropepi, D.; Pierantozzi, M.; Brusa, L.; Scarinat, E.; Mazone, P. Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson’s disease. *Brain*, 2007, 130(6 Pt 1), 1596-1607.

http://dx.doi.org/10.1093/brain/awl346 PMID: 17251240

Morita, H.; Hass, C.J.; Moro, E.; Sudhahom, A.; Kumar, R.; Okun, M.S. Parkinson Study Group. F. Pedunculopontine nucleus stimulation: Where are we now and what needs to be done to move the field forward? *Front. Neurol.*, 2014, 5, 243.

Lim, J.D.; Sobrinho, C.R.; Falquetto, B.; Santos, L.K.; Takakura, A.C.; Mulkey, D.K.; Moreira, T.S. Cholinergic neurons in the pedunculopontine tegmental nucleus modulate breathing in rats by direct projections to the retrotrapezoid nucleus. *J. Physiol.*, 2019, 597(7), 1919-1934.

http://dx.doi.org/10.1113/jpp.2017.177617 PMID: 30724347

Patel, S.; Ojo, O.; Genc, G.; Oravittakananu, S.; Huo, Y.; Rasamesoraj, T.; Wang, L.; Bena, J.; Drerup, M.; Foldvary-Schaefer, N.; Ahmed, A.; Fernandez, H.H. A Computerized Cognitive behavioral therapy Randomized, Controlled, pilot trial for insomnia in Parkinson disease (ACCORD-PD). *J. Clin. Mov. Disord.*, 2017, 4, 16-16.

http://dx.doi.org/10.1186/s40734-017-0062-2 PMID: 28852567

Haynes, P. Application of cognitive behavioral therapies for comorbid insomnia and depression. *Sleep Med. Clin.*, 2015, 10(1), 77-84.

http://dx.doi.org/10.1016/j.smcj.2014.11.006 PMID: 26055675

Zee, P.C. Timed light therapy for sleep and daytime sleepiness associated with parkinson disease: A randomized clinical trial. *JAMA Neurol.*, 2017, 74(4), 411-418.

http://dx.doi.org/10.1001/jamaneurol.2016.5192 PMID: 28241159

Martino, J.K.; Freelance, C.B.; Willis, G.L. The effect of light exposure on insomnia and nocturnal movement in Parkinson’s disease: An open label, retrospective, longitudinal study. *Sleep Med.*, 2018, 44, 24-31.

http://dx.doi.org/10.1016/j.sleep.2018.01.001 PMID: 29530365

Videnovic, A.; Klerman, E.B.; Wang, W.; Marconi, A.; Zee, P.C. Timed light therapy for sleep and daytime sleepiness associated with parkinson disease: A randomized clinical trial. *JAMA Neurol.*, 2017, 74(4), 411-418.

http://dx.doi.org/10.1001/jamaneurol.2016.5192 PMID: 28241159

Martino, J.K.; Freelance, C.B.; Willis, G.L. The effect of light exposure on insomnia and nocturnal movement in Parkinson’s disease: An open label, retrospective, longitudinal study. *Sleep Med.*, 2018, 44, 24-31.

http://dx.doi.org/10.1016/j.sleep.2018.01.001 PMID: 29530365

Humbert, M.; Findley, J.; Hernandez-Con, M.; Chahine, L.M. Cognitive behavioral therapy for insomnia in Parkinson’s disease: A case series. *NPJ Parkinsons Dis.*, 2017, 3, 25.

http://dx.doi.org/10.1038/s41531-017-0027-z PMID: 28765835

Osawa, C.; Kamei, Y.; Nozaki, K.; Furusawa, Y.; Murata, M. Brief Cognitive behavioral therapy for insomnia in Parkinson’s disease: A case series study. *Jpn. Psychol. Res.*, 2020, 2, 1-10.

http://dx.doi.org/10.1111/jpr.12287
Cammisuli, D.M.; Ceravolo, R.; Bonuccelli, U. Non-pharmacological interventions for Parkinson’s disease mild cognitive impairment: Future directions for research. *Neural Regen. Res.*, 2020, 15(9), 1650-1651. http://dx.doi.org/10.4103/1673-5374.276329 PMID: 32209764

Cupidi, C.; Realmuto, S.; Lo Coco, G.; Cinturino, A.; Talamanca, S.; Arnao, V.; Perini, V.; Piccoli, T.; D’Amelio, M.; Savettieri, G.; Lo Coco, D. Sleep quality in caregivers of patients with Alzheimer’s disease and Parkinson’s disease and its relationship to quality of life. *Int. Psychogeriatr.*, 2012, 24(11), 1827-1835. http://dx.doi.org/10.1017/S1041610212001032 PMID: 22652066

Skogar, O.; Borg, A.; Larsson, B.; Robertsson, L.; Andersson, L.; Backstrom, P.; Fall, P.A.; Hallgren, G.; Bringer, B.; Carlsson, M.; Lennartsson, U.; Sandbjork, H.; Lokk, J.; Tornhage, C.J. Effects of Tactile Touch on pain, sleep and health related quality of life in Parkinson’s disease with chronic pain: A randomized, controlled and prospective study. *Eur. J. Integr. Med.*, 2013, 5(2), 141-152. http://dx.doi.org/10.1016/j.eujim.2012.10.005

Modugno, N.; Iaconelli, S.; Fiorilli, M.; Lena, F.; Kusch, I.; Mirabella, G. Active theater as a complementary therapy for Parkinson’s disease rehabilitation: A pilot study. *Sci. World J.*, 2010, 10, 2301-2313.

Lee, J.; Kim, Y.; Kim, Y.L. Non-pharmacological therapies for sleep disturbances in people with Parkinson’s disease: A systematic review. *J. Adv. Nurs.*, 2018, 74(8), 1741-1751. http://dx.doi.org/10.1111/jan.13694 PMID: 29700848

Oikonomou, P.; van Wamelen, D.J.; Weintraub, D.; Aarsland, D.; Ffytche, D.; Martinez-Martin, P.; Rodriguez-Blazquez, C.; Leta, V.; Borley, C.; Sportelli, C.; Trivedi, D.; Podlewska, A.M.; Rukavina, K.; Rizos, A.; Lazcano-Ocampo, C.; Ray Chaudhuri, K. Nonmotor symptom burden grading as predictor of cognitive impairment in Parkinson’s disease. *Brain Behav.*, 2021, 11(5), e02086-e02086. http://dx.doi.org/10.1002/brb3.2086 PMID: 33645912

Powell, A.; Matar, E.; Lewis, S.J.G. Treating hallucinations in Parkinson’s disease. *Expert Rev. Neurother.*, 2020, 1-14. http://dx.doi.org/10.1080/14737155.2021.1851198 PMID: 33183105

Bartolomei, L.; Pastore, A.; Meligrana, L.; Sanson, E.; Bonetto, N.; Minicucci, G.M.; Marsala, S.Z.; Mesiano, T.; Bragagnolo, L.; Antonini, A. Relevance of sleep quality on caregiver burden in Parkinson’s disease. *Neurof. Sci.*, 2018, 39(5), 835-839. http://dx.doi.org/10.1007/s10072-018-3252-2 PMID: 29445989